In 2011, the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers (TF-CB) was formed, with the purpose of providing evidence based educational materials to assist all biomarker users, i.e. laboratorians, clinicians, researchers, in-vitro diagnostics and regulatory agencies, in better understanding important analytical and clinical aspects of established and novel cardiac biomarkers for use in clinical practice and research. The goal of the task force was to promulgate the same information conjointly through the in vitro diagnostic industry to the laboratory, emergency department and cardiologists. The initial undertaking of the TF-CB, which is comprised of laboratory medicine scientists, emergency medicine physicians and cardiolo...
A number of assay-related issues can affect the performance of cardiac troponin (cTn) measurement in...
The recently released document by the Global Task Force on the universal definition of myocardial in...
Two interferences recently brought to the forefront as patient safety issues include hemolysis (hemo...
In 2011, the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers (TF-CB) was formed, wit...
The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) formed a Task Forc...
The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-...
BACKGROUND: The primary role of the International Federation of Clinical Chemistry (IFCC) Committee ...
The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-...
The Committee on the Clinical Application of Cardiac Biomarkers (C-CB) of the International Federati...
The International Federation of Clinical Chemistry Committee on Clinical Applications of Cardiac Bio...
mended that an increased cardiac troponin should be defined as a measurement above the 99th percenti...
Background: As a part of an International Federation of Clinical Chemistry and Laboratory Medicine (...
Laboratory and clinical medicine groups are actively collaborating and optimizing their individual e...
Cardiac troponin assays have evolved substantially over 20 years, owing to the efforts of manufactur...
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.Trop...
A number of assay-related issues can affect the performance of cardiac troponin (cTn) measurement in...
The recently released document by the Global Task Force on the universal definition of myocardial in...
Two interferences recently brought to the forefront as patient safety issues include hemolysis (hemo...
In 2011, the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers (TF-CB) was formed, wit...
The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) formed a Task Forc...
The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-...
BACKGROUND: The primary role of the International Federation of Clinical Chemistry (IFCC) Committee ...
The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-...
The Committee on the Clinical Application of Cardiac Biomarkers (C-CB) of the International Federati...
The International Federation of Clinical Chemistry Committee on Clinical Applications of Cardiac Bio...
mended that an increased cardiac troponin should be defined as a measurement above the 99th percenti...
Background: As a part of an International Federation of Clinical Chemistry and Laboratory Medicine (...
Laboratory and clinical medicine groups are actively collaborating and optimizing their individual e...
Cardiac troponin assays have evolved substantially over 20 years, owing to the efforts of manufactur...
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.Trop...
A number of assay-related issues can affect the performance of cardiac troponin (cTn) measurement in...
The recently released document by the Global Task Force on the universal definition of myocardial in...
Two interferences recently brought to the forefront as patient safety issues include hemolysis (hemo...